US Bancorp DE reduced its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 1.3% in the 3rd quarter, Holdings Channel reports. The firm owned 91,342 shares of the company’s stock after selling 1,186 shares during the period. US Bancorp DE’s holdings in Henry Schein were worth $7,768,000 as of its most recent filing with the SEC.
Other hedge funds have also modified their holdings of the company. NEXT Financial Group Inc acquired a new position in shares of Henry Schein during the third quarter worth approximately $103,000. McAdam LLC acquired a new position in shares of Henry Schein during the third quarter worth approximately $104,000. Squar Milner Financial Services LLC acquired a new position in shares of Henry Schein during the second quarter worth approximately $120,000. Piedmont Investment Advisors LLC acquired a new position in shares of Henry Schein during the second quarter worth approximately $130,000. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Henry Schein by 57.1% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock worth $160,000 after buying an additional 800 shares during the last quarter.
A number of research analysts have recently commented on the company. BidaskClub upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Wednesday, August 22nd. Robert W. Baird upped their price target on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, August 7th. Stifel Nicolaus upped their price target on Henry Schein from $76.00 to $81.00 and gave the stock a “hold” rating in a report on Tuesday, August 7th. Craig Hallum upped their price target on Henry Schein from $83.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, August 7th. Finally, Zacks Investment Research lowered Henry Schein from a “buy” rating to a “hold” rating in a research note on Saturday, July 14th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $84.41.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.02. Henry Schein had a return on equity of 20.40% and a net margin of 3.00%. The firm had revenue of $3.28 billion for the quarter, compared to analysts’ expectations of $3.37 billion. During the same period in the prior year, the business posted $0.87 earnings per share. The business’s revenue was up 3.8% compared to the same quarter last year. Equities analysts anticipate that Henry Schein, Inc. will post 4.12 EPS for the current year.
Henry Schein Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Story: Understanding Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.